340B contractor boosts profits while driving up patient costs: Report

Becker's Healthcare January 15, 2025
Alexandra Murphy

Apexus, a key contractor for the 340B drug pricing program, has come under scrutiny for profiting off its expanding role in the program, which was initially designed to help safety-net hospitals provide discounted drugs to low-income patients, The New York Times reported Jan. 15.

Here are five things to know:

1. Apexus, a for-profit subsidiary of Vizient, has managed the 340B program for two decades. The program, designed to provide safety-net hospitals access to discounted drugs, has expanded significantly, with the company handling negotiations and overseeing drug distributions for hospitals.
2. The company’s role in the program has raised concerns, as its strategies to expand the program’s reach often result in higher prices for patients. Through its “purchasing...

Today's Sponsors

Today's Sponsor